p21(Waf1/cip1) expression [11]

British Journal of Dermatology

Volumn 136, Issue 5, 1997, Pages 803-

  Rees, J L ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53; BIOLOGICAL MARKER; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR;

ACTINIC KERATOSIS; ALLELISM; BOWEN DISEASE; GENE MUTATION; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; PROTEIN SYNTHESIS; HUMAN; KERATOSIS; METABOLISM; NOTE;

BIOLOGICAL MARKERS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; KERATOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031000340     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb03686.x     Document Type: Letter

References (5)

1. 1 Inohara S, Kitagawa K, Kitano Y. Coexpression of p21 Waf1/Cip1 and p53 in sun‐exposed natural epidermis. but not in neoplastic epidermis. Br J Dermatol 1996 ; 135: 717–20.
2. 1 Rehman I, Takata M, Wu YY, Rees JL. Genetic change in actinic keratoses. Oncogene 1996 ; 12: 2483–90.
3. 1 Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 1994 ; 344: 788–9.
4. 1 Campbell C, Quinn AG, Angus B, Rees JL. The relation between p 53 mutation and p 53 immunostaining in non‐melanoma skin cancer. Br J Dermatol 1993 ; 129: 235–41.
5. 1 Rees JL. Genertic alterations in non‐melanoma skin cancer. J Invest Dermatol 1994 ; 103: 747–50.